Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease

Bone Marrow Transplantation

Volumn 22, Issue 8, 1998, Pages 751-754

  Kanda, Y ^a,b   Tanaka, Y ^b   Shirakawa, K ^c   Yatomi, T ^c   Nakamura, N ^c   Kami, M ^b   Saito, T ^b   Izutsu, K ^b   Asai, T ^b   Yuji, K ^b   Ogawa, S ^b   Honda, H ^b   Mitani, K ^b   Chiba, S ^a,b   Yazaki, Y ^a,b   Hirai, H ^a,b  

^a Dept Cell Ther Transplant Med ^*  (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Bone marrow transplantation; Fas; Graft versus host disease; Soluble Fas ligand

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; DNA SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL;

EID: 0031736130     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701427     Document Type: Article

References (19)

1. Korngold B, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. J Exp Med 1978; 148: 1687-1698.
2. Prentice HG, Janossy G, Skeggs D et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone marrow transplantation for acute leukemia. Lancet 1982; ii: 700-703.
3. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
4. Leithäuser F, Dhein J, Mechtersheimer G et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-429.
5. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183: 2645-2656.
6. Braun MY, Lowin B, French L et al. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183: 657-661.
7. Hattori K, Hirano T, Ushiyama C et al. A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice. Blood 1997; 90: 542-548.
8. Via CS, Nguyen P, Shustov A et al. A major role for the Fas pathway in acute graft versus host disease. J Immunol 1996; 157: 5387-5393.
9. Kayagaki N, Kawasaki A, Ebata T et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182: 1777-1783.
10. Tanaka M, Suda T, Haze K et al. Fas ligand in human serum. Nature Med 1996; 2: 317-322.
11. Hattori K, Hirano T, Miyajima H et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor a on acute graft-versus-host disease pathologies. Blood 1998; 91: 4051-4055.
12. Tiberghien P, Racadot E, Lioure B et al. Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Transplantation 1991; 52: 475-480.
13. Miyamoto T, Akashi K, Hayashi S et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996; 17: 185-190.
14. Anel A, Buferne M, Boyer C et al. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur J Immunol 1994; 24: 2469-2476.
15. Lee S, Chong SY, Lee JW et al. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD. Bone Marrow Transplant 1997; 20: 883-888.
16. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med 1998; 4: 31-36.
17. Hervé P, Wijdenes J, Bergerat JP et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990; 75: 1017-1023.
18. Hervé P, Flesch M, Tiberghien P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor a antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362-3368.
19. Takahashi T, Tanaka M, Inazawa J et al. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 1994; 6: 1567-1574.